US stocks trimmed losses on Thursday, finishing mixed after President Trump's sweeping tariffs hit dozens of US trade ...

Shares of Eli Lilly (NYSE: LLY) were plunging 14.8% as of 11:14 a.m. ET on Thursday. The big drugmaker reported results for ...

Now, new clinical trial results suggest that an oral form of this medication may be coming soon—and the results so far are ...

Results from the Phase III ATTAIN-1 trial (NCT05869903) showed that the highest dose of orforglipron achieved an average ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall ...

GLP-1's, which are traditionally diabetes medications, have exploded in popularity since they were approved for weight-loss.

A slew or company results were causing big market moves ahead of the opening bell Thursday, and for many, earnings-beat wasn’t enough to prevent a selloff.

Eli Lilly stock crashes as late-stage data for weight-loss pill falls short of expectations. Analyst explains why data wasn't ...